Azelastine/fluticasone propionate - Cipla/Meda

Drug Profile

Azelastine/fluticasone propionate - Cipla/Meda

Alternative Names: Azelastine hydrochloride/fluticasone propionate; Duonase; Dymista; Dymistalan; Dymistin; Dymolin; Fluticasone propionate/azelastine hydrochloride; Flutista; MP 29-01; MP 29-02; MP-AzeFlu

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Meda
  • Developer Cipla; Meda
  • Class Antiallergics; Glucocorticoids; Phthalazines; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Histamine H1 receptor antagonists; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic rhinitis; Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 29 Sep 2017 USPTO grants a petition for inter partes review (IPR) filed by Argentum Pharmaceuticals and KVK Tech against challenged claims of last-expiring patent of azelastine hydrochloride/fluticasone propionate nasal spray
  • 17 Jul 2017 Perrigo settles litigation brought by Meda Pharmaceuticals and Cipla over ANDA submission in USA
  • 03 Mar 2017 Efficacy data from a phase III trial in Allergic rhinitis presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top